IKZF1 Variants Predicted Poor Outcomes in Acute Myeloid Leukemia Patients with CEBPA bZIP In-Frame Mutations

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• CCAAT/enhancer-binding protein alpha-basic leucine zipper in-frame (CEBPA bZIP-inf) mutations are known prognostic markers in acute myeloid leukemia (AML).
• Limited data exists on how clinical and genomic factors interact to influence outcomes in CEBPA bZIP-inf AML.

Purpose of the Study:

• To investigate the impact of integrating clinical and genomic features on the outcomes of patients with CEBPA bZIP-inf AML.
• To identify specific prognostic factors that predict event-free survival (EFS), relapse-free survival (RFS), and overall survival.

Main Methods:

• Retrospective review of clinical and genomic data from 224 CEBPA bZIP-inf AML patients.
• Multivariate Cox proportional hazards regression analysis to identify significant prognostic variables.
• Risk stratification based on identified adverse prognostic covariates for RFS.

Main Results:

• IKZF1 mutations/deletions and FLT3-ITD mutations were significantly associated with poorer EFS and RFS.
• Elevated WBC count, lower hemoglobin, non-intensive induction, and MRD positivity predicted adverse outcomes.
• A risk stratification model identified low-, intermediate-, and high-risk subgroups with significant differences in survival rates.

Conclusions:

• A subset of CEBPA bZIP-inf AML patients with specific adverse prognostic factors (e.g., IKZF1, FLT3-ITD mutations) can be identified.
• Hematopoietic stem cell transplantation should be strongly considered for this high-risk population to improve outcomes.